First Citizens Bank & Trust’s Teva Pharmaceuticals TEVA Stock Holding History

First Citizens Bank & Trust’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-45,556	Closed	-$1.65M	–	534
2016 Q4	$1.65M	Sell	45,556 -29,022	-39%	-$1.16M	0.18%	130
2016 Q3	$3.43M	Sell	74,578 -4,046	-5%	-$211K	0.31%	100
2016 Q2	$3.95M	Sell	78,624 -7,698	-9%	-$410K	0.35%	88
2016 Q1	$4.62M	Sell	86,322 -2,342	-3%	-$137K	0.39%	78
2015 Q4	$5.82M	Sell	88,664 -32,216	-27%	-$1.99M	0.42%	75
2015 Q3	$6.83M	Sell	120,880 -6,388	-5%	-$414K	0.51%	65
2015 Q2	$7.52M	Sell	127,268 -12,880	-9%	-$795K	0.52%	65
2015 Q1	$8.73M	Buy	140,148 +1,510	+1%	+$87.8K	0.6%	58
2014 Q4	$7.97M	Buy	138,638 +218	+0.2%	+$12.1K	0.61%	62
2014 Q3	$7.44M	Buy	138,420 +2,192	+2%	+$116K	0.61%	63
2014 Q2	$7.14M	Buy	+136,228	New	+$6.96M	0.61%	62

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

First Citizens Bank & Trust's TEVA Position: Q1 2017 in Review

First Citizens Bank & Trust sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 45,556 shares — an estimated $1.65M sold.

First Citizens Bank & Trust first reported a position in TEVA in Q2 2014 and held it in 11 quarters. The position peaked at $8.73M in Q1 2015. 688 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

First Citizens Bank & Trust reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
First Citizens Bank & Trust sold 45,556 Teva Pharmaceuticals shares in Q1 2017, an estimated $1.65M.
First Citizens Bank & Trust first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 11 quarters.
First Citizens Bank & Trust's Teva Pharmaceuticals position peaked at $8.73M in Q1 2015.
688 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on First Citizens Bank & Trust's 13F filing for Q1 2017, filed 25 Apr 2017.